Skip to NavigationSkip to content

Business Services

Top Ten most popular articles on Pharmafile.com this week!

This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from poor results in late stage studies. Lilly’s failure was so such that they decided to withdraw Latruvo from the market.

Gilead's CFO and Executive Vice President to depart in 2020

Image credit: Gilead, Associated Press

Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, is set to step down from her role effective 1 March 2020.

Washington joined the company in 2008 as CFO, and was promoted to Executive Vice President in 2014. In her role, she oversees Gilead’s Global Finance and Information Technology organisations.

The price of access: Can the NHS afford Orkambi?

Published on 29/04/19 at 11:43am

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in the NHS’ regulatory system. Matt Fellows explores where the core issues lie in the debate, and what can be done to prevent future breakdowns in communication for the good of patients.

Top Ten most popular articles on Pharmafile.com this week!

The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK access innovative cancer drugs, this week. The institute suggested a new approach to funding models was necessary in order to encourage innovation.

The call came as Pfizer’s head of immune-oncology joined cancer focused firm Aduro Biotech as the company’s new CMO. The move may lead to new and innovative immunotherapies. Meanwhile GSK exec Richard Saynor was named as Novartis subsidiary Sandoz’ new CEO.

Senior GSK exec Richard Saynor revealed as new Sandoz CEO

Published on: 26/04/19

Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor would be stepping up to lead Sandoz, its biosimilars and generics division, as CEO from no later than 1 August. 

He will step into the position which was originally vacated by ex-CEO Richard Francis at the end of March. The role has been filled on an interim basis since then.

Interactions with the Agencies During Drug Development

Published date: 
30/04/2019
Summary: 
NDA would like to invite you to join Professor Steffen Thirstrup, Director NDA Advisory Board, formerly Division Head at the Danish Medicines Agency and CHMP member and Dr Rosalind Cox, Principal consultant NDA UK, formerly Divisional VP with Abbot, share their experiences and provide their insights into making the most of the opportunities to interact with EU Agencies during the drug development process.

 

NDA would like to invite you to join  Professor Steffen Thirstrup, Director NDA Advisory Board, formerly Division Head at the Danish Medicines Agency and CHMP member and Dr Rosalind Cox, Principal consultant NDA UK, formerly Divisional VP with Abbot, share their experiences and provide their insights into making the most of the opportunities to interact with EU Agencies during the drug development process.

Senior GSK exec Richard Saynor revealed as new Sandoz CEO

Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor would be stepping up to lead Sandoz, its biosimilars and generics division, as CEO from no later than 1 August.  

He will step into the position which was originally vacated by ex-CEO Richard Francis at the end of March. The role has been filled on an interim basis since then.

Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk

Published on 24/04/19 at 11:29am

Novo Nordisk's VP and CMO discusses his leap from family medicine into the pharma industry, his biggest achievements, and how having diabetes himself has shaped his outlook on treatment throughout his career.

You are a trained medical doctor; how did that shape your early career?

Top Ten most popular articles on Pharmafile.com this week!

This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK announced redundancies as Janssen scored twice in Phase 3 trials in chronic kidney disease and HIV.

Insys Therapeutics names current CFO Andrew Long as company's new CEO

Published on: 17/04/19

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s new CEO.

The opioid drugmaker said the decision had come after Motahari agreed to step down from the position of President and CEO.

The firm, who have faced legal issues over the marketing of their fentanyl based spray Subsys, have seen a series of successions in recent years after CEO Michael Babich was arrested in 2016.

The company were thus keen to emphasise their leadership in the “development, manufacture and commercialization of pharmaceutical cannabinoids.”

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches